RecruitingRecruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801 · Hoffmann-La Roche
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Patients With Endocrine- Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer With Chromosome 8P Loss and Without a PIK3CA Mutation
About this study
A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).
Eligibility criteria
Inclusion Criteria:
* Women or men with histologically or cytologically confirmed carcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent
* Documented estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, defined as \>=1% of tumor cells stained positive based on the most recent tumor biopsy and assessed locally (Allison et al. 2020)
* Participants must not have received any prior systemic therapy for locally advanced unresectable or metastatic breast cancer (mBC) and must have progressed during adjuvant endocrine-based treatment or within 12 months after completing adjuvant endocrine-based therapy with an aromatase inhibitor or tamoxifen
* Confirmed biomarker eligibility as documented through central laboratory testing of a tumor tissue sample documenting both the lack of a phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation and the presence of heterozygous loss of chromosome 8p (i.e., PIK3CAnmd and chr8p loss)
* Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
Exclusion Criteria:
* Metaplastic breast cancer
* Radiotherapy within 2 weeks before randomization
* Appropriate for treatment with cytotoxic chemotherapy at time of entry into the study, as per national or local treatment guidelines (e.g., participants with visceral crisis)
* Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
* Known and untreated, or active Central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Participants with a history of treated CNS metastases are eligible
* Any history of leptomeningeal disease or carcinomatous meningitis
Study design
Enrollment target: 80 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-04-07
Estimated completion: 2030-02-26
Last updated: 2026-11-03
Interventions
Drug: InavolisibDrug: RibociclibDrug: FulvestrantDrug: Placebo
Primary outcomes
- • Percentage of Participants With Confirmed Objective Response (cORR) (Up to approximately 2 years)
Sponsor
Hoffmann-La Roche · industry
Contacts & investigators
ContactReference Study ID Number: CO46274 https://forpatients.roche.com/ No attachments to email below. · contact · global-roche-genentech-trials@gene.com · 888-662-6728
ContactFastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry · contact
InvestigatorClinical Trials · study_director, Hoffmann-La Roche
All locations (59)
Los Angeles Cancer Network - AnaheimRecruiting
Anaheim, California, United States
Stanford Cancer InstituteRecruiting
Palo Alto, California, United States
Cancer Specialists of North FloridaRecruiting
Jacksonville, Florida, United States
Avera Cancer Institute - MarshallRecruiting
Marshall, Minnesota, United States
Queens Hospital Cancer CenterRecruiting
Jamaica, New York, United States
Avera Cancer Institute - AberdeenRecruiting
Aberdeen, South Dakota, United States
Avera Cancer Institute - MitchellRecruiting
Mitchell, South Dakota, United States
Avera Cancer Institute - Pierre, SDRecruiting
Pierre, South Dakota, United States
Avera Cancer InstituteRecruiting
Sioux Falls, South Dakota, United States
AMG Oncology and Hematology Avera Cancer Institute - YanktonRecruiting
Yankton, South Dakota, United States
Medical College of WisconsinRecruiting
Milwaukee, Wisconsin, United States
Inst. Alexander FlemingRecruiting
Buenos Aires, Argentina
Centro Oncologico KorbenRecruiting
Caba, Argentina
Centro Médico FleischerRecruiting
Capital Federal, Argentina
Sanatorio de la MujerRecruiting
Rosario, Argentina
Hospital Santa Rita de Cassia VitoriaRecruiting
Vitória, Espírito Santo, Brazil
Hospital BrasiliaRecruiting
Brasília, Federal District, Brazil
Ictrials Pesquisa e DesenvolvimentoRecruiting
Curitiba, Paraná, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria LtdaRecruiting
São Paulo, São Paulo, Brazil
Ottawa General HospitalRecruiting
Ottawa, Ontario, Canada
Sunnybrook Health Science CentreRecruiting
Toronto, Ontario, Canada
CIUSSS du Saguenay Lac-Saint-Jean, Chicoutimi HospitalRecruiting
Chicoutimi, Quebec, Canada
McGill UniversityRecruiting
Montreal, Quebec, Canada
Centre Oscar LambretRecruiting
Lille, France
Centre Leon BerardRecruiting
Lyon, France
Institut Paoli CalmettesRecruiting
Marseille, France
Institut Régional du Cancer de MontpellierRecruiting
Montpellier, France
Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)Recruiting
Toulouse, France
Uniklinik RWTH Aachen Klinik für Gynäkologie und GeburtsmedizinRecruiting
Aachen, Germany
Städtisches Klinikum DessauRecruiting
Dessau, Germany
Universitätsklinikum EssenRecruiting
Essen, Germany
Nationales Centrum für Tumorerkrankungen (NCT)Recruiting
Heidelberg, Germany
Universitätsklinik TübingenRecruiting
Tübingen, Germany
Istituto Nazionale Tumori Irccs Fondazione g. PASCALERecruiting
Naples, Campania, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede MeldolaRecruiting
Meldola, Emilia-Romagna, Italy
Università Campus Bio-Medico di RomaRecruiting
Rome, Lazio, Italy
Asst Papa Giovanni XXIIIRecruiting
Bergamo, Lombardy, Italy
Ospedale San RaffaeleRecruiting
Milan, Lombardy, Italy
Irccs Istituto Nazionale Dei Tumori (Int)Recruiting
Milan, Lombardy, Italy
Instituto Nacional De CancerologiaRecruiting
Distrito Federal, Mexico CITY (federal District), Mexico
Centro de Investigacion Clinica de OaxacaRecruiting
Oaxaca City, Oaxaca, Mexico
Antiguo Hospital Civil de Guadalajara Fray Antonio AlcaldeRecruiting
Guadalajara, Mexico
Instytut "Centrum Zdrowia Matki Polki"Recruiting
?ód?, Poland
Bialostockie Centrum OnkologiiRecruiting
Bialystok, Poland
COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii DziennejRecruiting
Lublin, Poland
Dolno?l?skie Centrum OnkologiiRecruiting
Wroc?aw, Poland
Soon Chun Hyang University Cheonan HospitalRecruiting
Dongnam-gu, Cheonan-si, South Korea
Gachon University Gil Medical CenterRecruiting
Namdong-Gu, South Korea
Seoul National University Bundang HospitalRecruiting
Seongnam-si, South Korea
Seoul National University HospitalRecruiting
Seoul, South Korea
ICO L'HospitaletRecruiting
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Clinic BarcelonaRecruiting
Barcelona, Spain
Hospital Universitario Clínico San CecilioRecruiting
Granada, Spain
Hospital Ramon y CajalRecruiting
Madrid, Spain
Hospital Universitario 12 de OctubreRecruiting
Madrid, Spain
Hospital Clinico Universitario de ValenciaRecruiting
Valencia, Spain
Leicester Royal InfirmaryRecruiting
Leicester, United Kingdom
Royal Free HospitalRecruiting
London, United Kingdom
Christie Hospital Nhs TrustRecruiting
Manchester, United Kingdom